Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 373-393

  Shiley, Kevin ^a   Blumberg, Emily ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Herpes virus; HHV 6; HHV 7; Kaposi sarcoma; PTLD; Zoster

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; RAPAMYCIN; RITUXIMAB; VALACICLOVIR; VALGANCICLOVIR;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL RESISTANCE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; INFECTION PREVENTION; KAPOSI SARCOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PRIMARY EFFUSION LYMPHOMA; RECIPIENT; REVIEW; SEROPREVALENCE; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS 3, HUMAN; HERPESVIRUS 4, HUMAN; HERPESVIRUS 6, HUMAN; HERPESVIRUS 7, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION;

EID: 77952700252     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.01.003     Document Type: Review

References (223)

1. Balfour H.H., Chace B.A., Stapleton J.T., et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989, 320(21):1381-1387.
2. Snydman D.R. Epidemiology of infections after solid-organ transplantation. Clin Infect Dis 2001, 33(Suppl 1):S5-S8.
3. Montoya J., Giraldo L., Efron B., et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001, 33:629-640.
4. Singh N., Dummer J.S., Kusne S., et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988, 158(1):124-131.
5. Dummer J.S., Armstrong J., Somers J., et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 1987, 155(2):202-206.
6. Koneru B., Tzakis A.G., DePuydt L.E., et al. Transmission of fatal herpes simplex infection through renal transplantation. Transplantation 1988, 45(3):653-656.
7. Malkin J. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 2004, 11(Suppl 1):24.
8. Malkin J., Morand P., Malvy D. Seroprevalence of HSV-1 and HSV-2 in the general French population. Sex Transm Dis 2002, 78:201-203.
9. Vyse A., Gay N., Slomka M. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Dis 2000, 76:183-187.
10. Xu F., Sternberg M.R., Kottiri B.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296(8):964-973.
11. Gane E., Saliba F., Valdecasas G.J., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997, 350(9093):1729-1733.
12. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999, 340(19):1462-1470.
13. Meyers J.D., Flournoy N., Thomas E.D. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980, 142(3):338-346.
14. Meyers J.D., Wade J.C., Mitchell C.D., et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982, 73(1A):229-235.
15. Saral R., Burns W.H., Laskin O.L., et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981, 305(2):63-67.
16. Seale L., Jones C.J., Kathpalia S., et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985, 254(24):3435-3438.
17. Kusne S., Schwartz M., Breinig M.K., et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991, 163(5):1001-1007.
18. Pettersson E., Hovi T., Ahonen J., et al. Prophylactic oral acyclovir after renal transplantation. Transplantation 1985, 39(3):279-281.
19. Naraqi S., Jackson G.G., Jonasson O., et al. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis 1977, 136(4):531-540.
20. Corey L. Herpes simplex virus. Principles and practice of infectious diseases 2005, vol. 2:1762-1780. Elsevier, Philadelphia (PA). 6th edition. G. Mandell, J. Bennett, R. Dolin (Eds.).
21. Hann I.M., Prentice H.G., Blacklock H.A., et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983, 287(6389):384-388.
22. Buss D.H., Scharyj M. Herpesvirus infection of the esophagus and other visceral organs in adults. Incidence and clinical significance. Am J Med 1979, 66(3):457-462.
23. Cunha B.A., Eisenstein L.E., Dillard T., et al. Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy. Heart Lung 2007, 36(1):72-78.
24. Herout V., Vortel V., Vondrackova A. Herpes simplex involvement of the lower respiratory tract. Am J Clin Pathol 1966, 46(4):411-419.
25. Morgan H.R., Finland M. Isolation of herpes virus from a case of atypical pneumonia and erythema multiforme exudativum with studies of four additional cases. Am J Med Sci 1949, 217(1):92-95.
26. Nash G. Necrotizing tracheobronchitis and bronchopneumonia consistent with herpetic infection. Hum Pathol 1972, 3(2):283-291.
27. Nash G., Foley F.D. Herpetic infection of the middle and lower respiratory tract. Am J Clin Pathol 1970, 54(6):857-863.
28. Ramsey P.G., Fife K.H., Hackman R.C., et al. Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 1982, 97(6):813-820.
29. Bruynseels P., Jorens P.G., Demey H.E., et al. Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet 2003, 362(9395):1536-1541.
30. Camps K., Jorens P.G., Demey H.E., et al. Clinical significance of herpes simplex virus in the lower respiratory tract of critically ill patients. Eur J Clin Microbiol Infect Dis 2002, 21(10):758-759.
31. Klainer A.S., Oud L., Randazzo J., et al. Herpes simplex virus involvement of the lower respiratory tract following surgery. Chest 1994, 106(Suppl 1):8S-14S. [discussion: 34S-5S].
32. Liebau P., Kuse E., Winkler M., et al. Management of herpes simplex virus type 1 pneumonia following liver transplantation. Infection 1996, 24(2):130-135.
33. Tuxen D.V., Wilson J.W., Cade J.F. Prevention of lower respiratory herpes simplex virus infection with acyclovir in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1987, 136(2):402-405.
34. Schuller D., Spessert C., Fraser V.J., et al. Herpes simplex virus from respiratory tract secretions: epidemiology, clinical characteristics, and outcome in immunocompromised and nonimmunocompromised hosts. Am J Med 1993, 94(1):29-33.
35. Campsen J., Hendrickson R., Bak T., et al. Herpes simplex in a liver transplant recipient. Liver Transpl 2006, 12(7):1171-1173.
36. Basse G., Mengelle C., Kamar N., et al. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation. Infection 2008, 36(1):62-64.
37. Duckro A.N., Sha B.E., Jakate S., et al. Herpes simplex virus hepatitis: expanding the spectrum of disease. Transpl Infect Dis 2006, 8(3):171-176.
38. Kaufman B., Gandhi S.A., Louie E., et al. Herpes simplex virus hepatitis: case report and review. Clin Infect Dis 1997, 24(3):334-338.
39. Taylor R.J., Saul S.H., Dowling J.N., et al. Primary disseminated herpes simplex infection with fulminant hepatitis following renal transplantation. Arch Intern Med 1981, 141(11):1519-1521.
40. Bissig K.D., Zimmermann A., Bernasch D., et al. Herpes simplex virus hepatitis 4 years after liver transplantation. J Gastroenterol 2003, 38(10):1005-1008.
41. Adler M., Goldman M., Liesnard C., et al. Diffuse herpes simplex virus colitis in a kidney transplant recipient successfully treated with acyclovir. Transplantation 1987, 43(6):919-921.
42. Delis S., Kato T., Ruiz P., et al. Herpes simplex colitis in a child with combined liver and small bowel transplant. Pediatr Transplant 2001, 5(5):374-377.
43. el-Serag H.B., Zwas F.R., Cirillo N.W., et al. Fulminant herpes colitis in a patient with Crohn's disease. J Clin Gastroenterol 1996, 22(3):220-223.
44. Fishbein P.G., Tuthill R., Kressel H., et al. Herpes simplex esophagitis: a cause of upper-gastrointestinal bleeding. Dig Dis Sci 1979, 24(7):540-544.
45. Howiler W., Goldberg H.I. Gastroesophageal involvement in herpes simplex. Gastroenterology 1976, 70(5 Pt 1):775-778.
46. Mosimann F., Cuenoud P.F., Steinhauslin F., et al. Herpes simplex esophagitis after renal transplantation. Transpl Int 1994, 7(2):79-82.
47. Naik H.R., Chandrasekar P.H. Herpes simplex virus (HSV) colitis in a bone marrow transplant recipient. Bone Marrow Transplant 1996, 17(2):285-286.
48. Watts S.J., Alexander L.C., Fawcett K., et al. Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report. Am J Gastroenterol 1986, 81(3):185-188.
49. Gomez E., Melon S., Aguado S., et al. Herpes simplex virus encephalitis in a renal transplant patient: diagnosis by polymerase chain reaction detection of HSV DNA. Am J Kidney Dis 1997, 30(3):423-427.
50. Raschilas F., Wolff M., Delatour F., et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis 2002, 35(3):254-260.
51. Lakeman F.D., Whitley R.J. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995, 171(4):857-863.
52. Whitley R.J., Alford C.A., Hirsch M.S., et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986, 314(3):144-149.
53. Shepp D.H., Dandliker P.S., Flournoy N., et al. Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation. J Antimicrob Chemother 1985, 16(3):389-395.
54. Chen Y., Scieux C., Garrait V., et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000, 31(4):927-935.
55. Erard V., Wald A., Corey L., et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007, 196(2):266-270.
56. Morfin F., Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003, 26(1):29-37.
57. Nugier F., Colin J.N., Aymard M., et al. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 1992, 36(1):1-12.
58. Herpes simplex virus (HSV)-1 and -2, and varicella zoster virus (VZV). Am J Transplant 2004, 4(s10):69-71.
59. Alcaide M.L., Abbo L., Pano J.R., et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant 2008, 22(4):502-507.
60. Arness T., Pedersen R., Dierkhising R., et al. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis 2008, 10(4):260-268.
61. Manuel O., Kumar D., Singer L.G., et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008, 27(1):11-16.
62. Locksley R.M., Flournoy N., Sullivan K.M., et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985, 152(6):1172-1181.
63. Boeckh M., Kim H.W., Flowers M.E., et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood 2006, 107(5):1800-1805.
64. Han C.S., Miller W., Haake R., et al. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994, 13(3):277-283.
65. Leung T.F., Chik K.W., Li C.K., et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant 2000, 25(2):167-172.
66. Koc Y., Miller K.B., Schenkein D.P., et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000, 6(1):44-49.
67. Gnann J. Herpes simplex and varicella zoster virus infection after hemopoietic stem cell or solid organ transplantation 2003, Lippincott, Williams and Wilkins, Philadelphia.
68. Fuks L., Shitrit D., Fox B.D., et al. Herpes zoster after lung transplantation: incidence, timing, and outcome. Ann Thorac Surg 2009, 87(2):423-426.
69. Gourishankar S., McDermid J.C., Jhangri G.S., et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004, 4(1):108-115.
70. Herrero J.I., Quiroga J., Sangro B., et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl 2004, 10(9):1140-1143.
71. Lauzurica R., Bayes B., Frias C., et al. Disseminated varicella infection in adult renal allograft recipients: role of mycophenolate mofetil. Transplant Proc 2003, 35(5):1758-1759.
72. Weinberg A., Horslen S.P., Kaufman S.S., et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006, 6(3):565-568.
73. Khan S., Erlichman J., Rand E.B. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006, 10(1):78-82.
74. Kraft J.N., Shaw J.C. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol 2006, 142(7):943-945.
75. Levitsky J., Te H.S., Faust T.W., et al. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant 2002, 2(9):880-882.
76. Sauerbrei A., Prager J., Hengst U., et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997, 20(5):381-383.
77. Merck Varivax varicella virus vaccine live [PDF file]. Available at:, Accessed August 8, 2009. http://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf.
78. Hata A., Asanuma H., Rinki M., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002, 347(1):26-34.
79. Feldhoff C.M., Balfour H.H., Simmons R.L., et al. Varicella in children with renal transplants. J Pediatr 1981, 98(1):25-31.
80. McGregor R.S., Zitelli B.J., Urbach A.H., et al. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 1989, 83(2):256-261.
81. Parnham A.P., Flexman J.P., Saker B.M., et al. Primary varicella in adult renal transplant recipients: a report of three cases plus a review of the literature. Clin Transplant 1995, 9(2):115-118.
82. Fall A.J., Aitchison J.D., Krause A., et al. Donor organ transmission of varicella zoster due to cardiac transplantation. Transplantation 2000, 70(1):211-213.
83. Hyland J.M., Butterworth J. Severe acute visceral pain from varicella zoster virus. Anesth Analg 2003, 97(4):1117-1118.
84. Koskiniemi M., Piiparinen H., Rantalaiho T., et al. Acute central nervous system complications in varicella zoster virus infections. J Clin Virol 2002, 25(3):293-301.
85. Aberle S.W., Puchhammer-Stockl E. Diagnosis of herpesvirus infections of the central nervous system. J Clin Virol 2002, 25(Suppl 1):S79-S85.
86. Puchhammer-Stockl E., Popow-Kraupp T., Heinz F.X., et al. Detection of varicella-zoster virus DNA by polymerase chain reaction in the cerebrospinal fluid of patients suffering from neurological complications associated with chicken pox or herpes zoster. J Clin Microbiol 1991, 29(7):1513-1516.
87. Glaser C.A., Honarmand S., Anderson L.J., et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis 2006, 43(12):1565-1577.
88. Gilden D. Varicella zoster virus and central nervous system syndromes. Herpes 2004, 11(Suppl 2):89A-94A.
89. Tyring S., Belanger R., Bezwoda W., et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001, 19(1):13-22.
90. American Academy of Pediatrics Varicella zoster virus 2000, American Academy of Pediatrics, Elk Grove (IL). 25th edition.
91. Marin M., Guris D., Chaves S.S., et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR-4):1-40.
92. A new product (VariZIG™) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006, 55(8):209-210.
93. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 2004, 4(Suppl 10):59-65.
94. Nalesnik M.A. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001, 3(2):88-96.
95. Preiksaitis J.K. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 2004, 39(7):1016-1023.
96. Karras A., Thervet E., Legendre C. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation 2004, 77(2):238-243.
97. Lee E.S., Locker J., Nalesnik M., et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995, 332(1):19-25.
98. Jenkins F.J., Rowe D.T., Rinaldo C.R. Herpesvirus infections in organ transplant recipients. Clin Diagn Lab Immunol 2003, 10(1):1-7.
99. Johannsen E., Schooley R., Kaye K. Epstein-Barr virus (infectious mononucleosis). Principles and practice of infectious diseases 2005, vol. 2:1801-1820. Elsevier, Philadelphia (PA). G. Mandell, J. Bennett, R. Dolin (Eds.).
100. Baskin H.J., Hedlund G. Neuroimaging of herpesvirus infections in children. Pediatr Radiol 2007, 37(10):949-963.
101. Alfieri C., Tanner J., Carpentier L., et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 1996, 87(2):812-817.
102. Haque T., Thomas J.A., Falk K.I., et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996, 77(Pt 6):1169-1172.
103. Frizzera G., Hanto D.W., Gajl-Peczalska K.J., et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981, 41(11 Pt 1):4262-4279.
104. Hanto D.W., Gajl-Peczalska K.J., Frizzera G., et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 1983, 198(3):356-369.
105. Yousem S.A., Randhawa P., Locker J., et al. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum Pathol 1989, 20(4):361-369.
106. Diaz-Guzman E., Farver C., Kanne J.P., et al. A 65-year-old man with odynophagia and a lung mass. Chest 2009, 135(3):876-879.
107. Khan M.S., Ahmed S., Challacombe B., et al. Post-transplant lymphoproliferative disorder (PTLD) presenting as painful lymphocele 12 years after a cadaveric renal transplant. Int Urol Nephrol 2008, 40(2):547-550.
108. Lee W.K., Lau E.W., Duddalwar V.A., et al. Abdominal manifestations of extranodal lymphoma: spectrum of imaging findings. AJR Am J Roentgenol 2008, 191(1):198-206.
109. Kunitomi A., Arima N., Ishikawa T. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab. Haematologica 2007, 92(4):e49-e52.
110. Ellis D., Jaffe R., Green M., et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999, 68(7):997-1003.
111. Ho M., Miller G., Atchison R.W., et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985, 152(5):876-886.
112. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990, 323(25):1723-1728.
113. Walker R.C., Marshall W.F., Strickler J.G., et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995, 20(5):1346-1353.
114. Keay S., Oldach D., Wiland A., et al. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 1998, 26(3):596-600.
115. Cox K.L., Lawrence-Miyasaki L.S., Garcia-Kennedy R., et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995, 59(4):524-529.
116. Manez R., Breinig M.C., Linden P., et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997, 176(6):1462-1467.
117. Weinstock D.M., Ambrossi G.G., Brennan C., et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006, 37(6):539-546.
118. Preiksaitis J.K., Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001, 33(Suppl 1):S38-S46.
119. Tsai D.E., Douglas L., Andreadis C., et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008, 8(5):1016-1024.
120. Wheless S.A., Gulley M.L., Raab-Traub N., et al. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med 2008, 178(10):1060-1065.
121. Harris N.L. Posttransplant lymphoproliferative disorders (PTLD). Pathology and genetics: tumours of haematopoietic and lymphoid tissues. WHO classification of tumours 2001, IARC Press, Lyon (France), p. 264-9. E. Jaffe, N. Harris, H. Stein (Eds.).
122. Harris N.L., Ferry J.A., Swerdlow S.H. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997, 14(1):8-14.
123. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1(8377):583-587.
124. Tsai D.E., Hardy C.L., Tomaszewski J.E., et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001, 71(8):1076-1088.
125. Hanto D.W., Frizzera G., Gajl-Peczalska K.J., et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982, 306(15):913-918.
126. Andersson J., Skoldenberg B., Ernberg I., et al. Acyclovir treatment in primary Epstein-Barr virus infection. A double-blind placebo-controlled study. Scand J Infect Dis Suppl 1985, 47:107-115.
127. Paya C.V., Fung J.J., Nalesnik M.A., et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999, 68(10):1517-1525.
128. Yao Q.Y., Ogan P., Rowe M., et al. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989, 43(1):67-71.
129. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107(8):3053-3057.
130. Norin S., Kimby E., Ericzon B.G., et al. Posttransplant lymphoma-a single-center experience of 500 liver transplantations. Med Oncol 2004, 21(3):273-284.
131. Trappe R.U., Choquet S., Reinke P., et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single-agent rituximab. Transplantation 2007, 84(12):1708-1712.
132. Oertel S.H., Verschuuren E., Reinke P., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005, 5(12):2901-2906.
133. Rooney C.M., Smith C.A., Ng C.Y.C., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92(5):1549-1555.
134. Gustafsson A., Levitsky V., Zou J.-Z., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000, 95(3):807-814.
135. Savoldo B., Goss J.A., Hammer M.M., et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006, 108(9):2942-2949.
136. Haque T., Taylor C., Wilkie G.M., et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001, 72(8):1399-1402.
137. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110(4):1123-1131.
138. Haque T., Wilkie G.M., Taylor C., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360(9331):436-442.
139. Comoli P., Labirio M., Basso S., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002, 99(7):2592-2598.
140. Khanna R., Bell S., Sherritt M., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999, 96(18):10391-10396.
141. Choquet S., Trappe R., Leblond V., et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007, 92(2):273-274.
142. Elstrom R.L., Andreadis C., Aqui N.A., et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006, 6(3):569-576.
143. Garrett T.J., Chadburn A., Barr M.L., et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993, 72(9):2782-2785.
144. Mamzer-Bruneel M.F., Lome C., Morelon E., et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000, 18(21):3622-3632.
145. Everly M.J., Bloom R.D., Tsai D.E., et al. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007, 41(11):1850-1858.
146. Karras A., Thervet E., Le Meur Y., et al. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant 2004, 4(11):1904-1909.
147. Darenkov I.A., Marcarelli M.A., Basadonna G.P., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997, 64(6):848-852.
148. Davis C.L., Harrison K.L., McVicar J.P., et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995, 9(1):53-59.
149. Funch D.P., Walker A.M., Schneider G., et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005, 5(12):2894-2900.
150. Green M., Kaufmann M., Wilson J., et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997, 25(6):1344-1349.
151. Bakker N.A., Verschuuren E.A., Erasmus M.E., et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007, 83(4):433-438.
152. Salahuddin S.Z., Ablashi D.V., Markham P.D., et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986, 234(4776):596-601.
153. Gentile G. Post-transplant HHV-6 diseases. Herpes 2000, 7(1):24-27.
154. Leach C.T., Sumaya C.V., Brown N.A. Human herpesvirus-6: clinical implications of a recently discovered, ubiquitous agent. J Pediatr 1992, 121(2):173-181.
155. Brown N.A., Sumaya C.V., Liu C.R., et al. Fall in human herpesvirus 6 seropositivity with age. Lancet 1988, 2(8607):396.
156. Lau Y.L., Peiris M., Chan G.C., et al. Primary human herpes virus 6 infection transmitted from donor to recipient through bone marrow infusion. Bone Marrow Transplant 1998, 21(10):1063-1066.
157. Cervera C., Marcos M.A., Linares L., et al. A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients. Transplantation 2006, 82(7):979-982.
158. Zerr D.M., Corey L., Kim H.W., et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005, 40(7):932-940.
159. de Pagter P.J., Schuurman R., Meijer E., et al. Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. J Clin Virol 2008, 43(4):361-366.
160. de Pagter P.J., Schuurman R., Visscher H., et al. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant 2008, 14(7):831-839.
161. Wang L.R., Dong L.J., Zhang M.J., et al. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12(10):1031-1037.
162. Yamane A., Mori T., Suzuki S., et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant 2007, 13(1):100-106.
163. DesJardin J.A., Gibbons L., Cho E., et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998, 178(6):1783-1786.
164. Dockrell D.H., Prada J., Jones M.F., et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997, 176(5):1135-1140.
165. Lehto J.T., Halme M., Tukiainen P., et al. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007, 26(1):41-47.
166. Ratnamohan V.M., Chapman J., Howse H., et al. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Transplantation 1998, 66(7):877-882.
167. Yoshikawa T., Suga S., Asano Y., et al. A prospective study of human herpesvirus-6 infection in renal transplantation. Transplantation 1992, 54(5):879-883.
168. Humar A., Malkan G., Moussa G., et al. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000, 181(4):1450-1453.
169. Herbein G., Strasswimmer J., Altieri M., et al. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients. Clin Infect Dis 1996, 22(1):171-173.
170. Razonable R.R., Paya C.V. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002, 8(8):651-658.
171. Humar A., Asberg A., Kumar D., et al. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009, 9(2):374-381.
172. Singh N., Paterson D.L. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000, 69(12):2474-2479.
173. Bollen A.E., Wartan A.N., Krikke A.P., et al. Amnestic syndrome after lung transplantation by human herpes virus-6 encephalitis. J Neurol 2001, 248(7):619-620.
174. Mookerjee B.P., Vogelsang G. Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transplant 1997, 20(10):905-906.
175. Mori T., Mihara A., Yamazaki R., et al. Myelitis associated with human herpes virus 6 (HHV-6) after allogeneic cord blood transplantation. Scand J Infect Dis 2007, 39(3):276-278.
176. Seeley W.W., Marty F.M., Holmes T.M., et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007, 69(2):156-165.
177. Vu T., Carrum G., Hutton G., et al. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 39(11):705-709.
178. Fotheringham J., Akhyani N., Vortmeyer A., et al. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis 2007, 195(3):450-454.
179. Luppi M., Barozzi P., Maiorana A., et al. Human herpesvirus 6 infection in normal human brain tissue. J Infect Dis 1994, 169(4):943-944.
180. Caserta M.T., McDermott M., Dewhurst S., et al. Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr 2004, 145(4):478-484.
181. Singh N., Carrigan D.R., Gayowski T., et al. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation 1995, 60(11):1355-1357.
182. Revest M., Camus C., D'Halluin P.N., et al. Fatal human herpes virus 6 primary infection after liver transplantation. Transplantation 2007, 83(10):1404-1405.
183. Randhawa P.S., Jenkins F.J., Nalesnik M.A., et al. Herpesvirus 6 variant A infection after heart transplantation with giant cell transformation in bile ductular and gastroduodenal epithelium. Am J Surg Pathol 1997, 21(7):847-853.
184. Burns W.H., Sandford G.R. Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis 1990, 162(3):634-637.
185. Agut H., Aubin J.T., Huraux J.M. Homogeneous susceptibility of distinct human herpesvirus 6 strains to antivirals in vitro. J Infect Dis 1991, 163(6):1382-1383.
186. Reymen D., Naesens L., Balzarini J., et al. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res 1995, 28(4):343-357.
187. Ward K.N. Human herpesviruses-6 and -7 infections. Curr Opin Infect Dis 2005, 18(3):247-252.
188. Ward K.N., White R.P., Mackinnon S., et al. Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. Bone Marrow Transplant 2002, 30(12):983-985.
189. Yoshikawa T., Yoshida J., Hamaguchi M., et al. Human herpesvirus 7-associated meningitis and optic neuritis in a patient after allogeneic stem cell transplantation. J Med Virol 2003, 70(3):440-443.
190. Kidd I.M., Clark D.A., Sabin C.A., et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000, 69(11):2400-2404.
191. Osman H.K., Peiris J.S., Taylor C.E., et al. " Cytomegalovirus disease" in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression?. J Med Virol 1996, 48(4):295-301.
192. Tong C.Y., Bakran A., Williams H., et al. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 2000, 70(1):213-216.
193. Moore P.S., Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995, 332(18):1181-1185.
194. Cesarman E., Chang Y., Moore P.S., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995, 332(18):1186-1191.
195. Antman K., Chang Y. Kaposi's sarcoma. N Engl J Med 2000, 342(14):1027-1038.
196. Moore P.S. The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). N Engl J Med 2000, 343(19):1411-1413.
197. Melbye M., Cook P.M., Hjalgrim H., et al. Risk factors for Kaposi's-sarcoma-associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996. Int J Cancer 1998, 77(4):543-548.
198. Ahmadpoor P., Ilkhanizadeh B., Sharifzadeh P., et al. Seroprevalence of human herpes virus-8 in renal transplant recipients: a single center study from Iran. Transplant Proc 2007, 39(4):1000-1002.
199. Butler L.M., Dorsey G., Hladik W., et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis 2009, 200(3):430-438.
200. Fu B., Sun F., Li B., et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Xinjiang, China. J Med Virol 2009, 81(8):1422-1431.
201. Engels E.A., Atkinson J.O., Graubard B.I., et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007, 196(2):199-207.
202. Human herpesvirus-8 (HHV-8, KSHV). Am J Transplant 2004, 4(s10):67-69.
203. Dudderidge T.J., Khalifa M., Jeffery R., et al. Donor-derived human herpes virus 8-related Kaposi's sarcoma in renal allograft ureter. Transpl Infect Dis 2008, 10(3):221-226.
204. Luppi M., Barozzi P., Schulz T.F., et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000, 343(19):1378-1385.
205. Parravicini C., Olsen S.J., Capra M., et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 1997, 90(7):2826-2829.
206. Bergallo M., Costa C., Margio S., et al. Human herpes virus 8 infection in kidney transplant patients from an area of northwestern Italy (Piemonte region). Nephrol Dial Transplant 2007, 22(6):1757-1761.
207. Boeckle E., Boesmueller C., Wiesmayr S., et al. Kaposi sarcoma in solid organ transplant recipients: a single center report. Transplant Proc 2005, 37(4):1905-1909.
208. Verucchi G., Calza L., Trevisani F., et al. Human herpesvirus-8-related Kaposi's sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. Transpl Infect Dis 2005, 7(1):34-37.
209. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005, 352(13):1317-1323.
210. Lebbe C., Euvrard S., Barrou B., et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006, 6(9):2164-2168.
211. Robles R., Lugo D., Gee L., et al. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20(1):34-38.
212. Little R.F., Merced-Galindez F., Staskus K., et al. A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis 2003, 187(1):149-153.
213. Jones D., Ballestas M.E., Kaye K.M., et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998, 339(7):444-449.
214. Al Otaibi T., Al Sagheir A., Ludwin D., et al. Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report. Transplant Proc 2007, 39(4):1276-1277.
215. Cagirgan S., Cirit M., Ok E., et al. Castleman's disease in a renal allograft recipient. Nephron 1997, 76(3):352-353.
216. Dotti G., Fiocchi R., Motta T., et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999, 13(5):664-670.
217. Melo N.C., Sales M.M., Santana A.N., et al. Pleural primary effusion lymphoma in a renal transplant recipient. Am J Transplant 2008, 8(4):906-907.
218. Stebbing J., Pantanowitz L., Dayyani F., et al. HIV-associated multicentric Castleman's disease. Am J Hematol 2008, 83(6):498-503.
219. Soulier J., Grollet L., Oksenhendler E., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86(4):1276-1280.
220. Mandel C., Silberstein M., Hennessy O. Case report: fatal pulmonary Kaposi's sarcoma and Castleman's disease in a renal transplant recipient. Br J Radiol 1993, 66(783):264-265.
221. Theate I., Michaux L., Squifflet J.P., et al. Human herpesvirus 8 and Epstein-Barr virus-related monotypic large B-cell lymphoproliferative disorder coexisting with mixed variant of Castleman's disease in a lymph node of a renal transplant recipient. Clin Transplant 2003, 17(5):451-454.
222. Casper C. Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection. Herpes 2006, 13(2):42-47.
223. Gaidano G., Carbone A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. Adv Cancer Res 2001, 80:115-146.